BNP/CALL/ELI LILLY & CO/500/0.1/17.01.25 | Market Closed - Boerse Frankfurt Warrants 20:50:27 05/07/2024 BST | ||
| 39.74 EUR | +2.90% |
|
| Current month | +0.40% | ||
| 1 month | +23.04% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
Latest news about ELI LILLY AND COMPANY
| Date | Price | Change |
|---|---|---|
| 05/07/24 | 39.84 | +3.16% |
| 04/07/24 | 38.62 | +0.52% |
| 03/07/24 | 38.42 | -2.64% |
| 02/07/24 | 39.46 | -1.08% |
| 01/07/24 | 39.89 | +0.53% |
Real-time Boerse Frankfurt Warrants
Last update July 05, 2024 at 08:50 pm
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | 
BNP Paribas
|
| WKN | PZ1XP4 |
| ISIN | DE000PZ1XP45 |
| Date issued | 30/11/2023 |
| Strike | 500 $ |
| Maturity | 17/01/2025 (195 Days) |
| Parity | 10 : 1 |
| Emission price | 13.92 € |
| Emission volume | N/A |
| Settlement | Barausgleich |
| Currency | EUR |
Technical Indicators
| Highest since issue | 40.39 € |
|---|---|
| Lowest since issue | 11.83 € |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
914.6
USD
Average target price
870.3
USD
Spread / Average Target
-4.84%
- Stock Market
- Warrants
- Warrant
